Objective-To investigate the effects of peroxisome proliferator-activated receptor (PPAR)␦ in the cerebral vasculature following stroke-induced brain injury. Methods and Results-Here, we report a novel finding that selective PPAR␦ genetic deletion in vascular smooth muscle cells (VSMCs) resulted in increased cerebrovascular permeability and brain infarction in mice after middle cerebral artery occlusion (MCAO). Mechanistically, we revealed for the first time that PPAR␦ expression is reduced, but matrix metalloproteinase (MMP)-9 activity is increased in cultured VSMCs after oxygen-glucose deprivation and also in the cerebral cortex of mice following MCAO. Moreover, gain-and loss of PPAR␦ function in VSMCs significantly reduces and increases oxygen-glucose deprivation-induced MMP-9 activity, respectively. We have further identified that MMP-9 is a direct target of PPAR␦-mediated transrepression by chromatin immunoprecipitation and PPAR␦ transcriptional activity assays. Furthermore, inhibition of MMP-9 activity by lentiviral MMP-9 short hairpin RNA effectively improves cerebrovascular permeability and reduces brain infarction in VSMC-selective PPAR␦ conditional knockout mice after MCAO. Conclusion-Our data demonstrate that PPAR␦ in VSMCs can prevent ischemic brain injury by inhibition of MMP-9 activation and attenuation of postischemic inflammation. The pharmacological activation of PPAR␦ may provide a new therapeutic strategy to treat stroke-induced vascular and neuronal damage. (Arterioscler Thromb Vasc Biol. 2011;31: 574-581.)
T he cerebral vasculature is a major target of ischemic insult in the brain. Activation of vascular cells, along with attendant extracellular matrix degradation and subsequent inflammatory responses, contribute to vascular injury, resulting in blood-brain barrier (BBB) disruption, hemorrhagic transformation, and eventual neuronal loss after cerebral ischemia. 1, 2 As one of the major cell types in the brain vasculature, vascular smooth muscle cells (VSMCs) play a dominant role in the regulation of cerebral vascular tone, vascular integrity and cerebral homeostasis in physiological conditions. However, the pathological role and molecular mechanisms of VSMCs in cerebral ischemia are largely unknown.
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors in which three distinct isoforms (PPAR␣, -␥, and -␦) have been identified in tissue. Beyond the initially identified metabolic effects, PPAR activation also induces antiinflammatory effects in the brain and, thus, may serve as a new pharmacological target for the treatment of neurological diseases. 3 Recently, accumulating evidence suggests that PPAR␥ activation by thiazolidinediones (TZDs), a class of synthetic ligands used to treat type 2 diabetes, 4 reduces infarct size and improves functional recovery from stroke in rodent models. 5, 6 Although most studies have shown that PPAR␥ and PPAR␣ agonists exert neuroprotective effects in rodent models of cerebral ischemia, the role of PPAR␦, the highest expressed PPAR subtype in brain parenchyma and the cerebral vasculature, is poorly understood in the context of ischemic stroke. 7 The matrix metalloproteinase (MMP) family is a class of zinc-dependent endoproteases responsible for degradation of structural proteins in the extracellular matrix. 8 Activation of MMPs plays an important role in the pathogenesis of various neurological diseases, including stroke. For example, mice with a genetic deletion of either the MMP-2 or MMP-9 gene are resistant to stroke-triggered vascular and brain parenchymal damage. 9, 10 Of significance, because of their destructive potential, MMPs are tightly controlled at multiple levels in physiological conditions. 11 Several recent studies have documented that MMP activity in vascular cells is negatively regulated by PPAR␥. 12, 13 However, whether PPAR␦ is able to regulate MMP expression is still largely unexplored.
In the present study, we used mice with VSMC-selective PPAR␦ deletion to explore the effects and molecular mechanisms of vascular PPAR␦ on ischemia-induced brain injury. We have identified for the first time that MMP-9 is a novel target of PPAR␦ transrepression, and this inhibition contributes to PPAR␦-mediated vascular and neuronal protection against ischemic insults.
Methods

Mouse Model of Transient Focal Cerebral Ischemia
VSMC-selective PPAR␦ knockout (SMP␦ cKO) and littermate control (LC) mice were subjected to middle cerebral artery occlusion (MCAO) for 30 minutes followed by 24 hours of reperfusion. 14
Cell Cultures
Primary VSMCs were obtained from wild-type mouse aortas. 15
Oxygen-Glucose Deprivation
To mimic ischemia-like conditions in vitro, cell cultures were exposed to oxygen-glucose deprivation (OGD). 14
Statistical Analysis
Quantitative data were expressed as meansϮSD or SEM and analyzed using Prism Software. Statistical comparisons between 2 groups were performed by Student t test, and comparisons among 3 or more groups were analyzed by 1-way ANOVA. Groups were considered significantly different if probability values were Ͻ0.05.
Results
VSMC-Specific PPAR␦ Deletion Potentiates Brain Injury in Mice After Focal Cerebral Ischemia
To investigate the role of PPAR␦ in VSMCs, we generated VSMC-selective PPAR␦ knockout (SMP␦ cKO) mice by crossing PPAR␦ flox/flox mice 16 with SM22␣-Cre knock-in mice that we previously developed. 17 The Western blot, as shown in supplemental Figure I (see the online Data Supplement at http://atvb.ahajournals.org), confirms that PPAR␦ protein expression was completely absent in aortic smooth muscle cells of SMP␦ cKO mice, whereas PPAR␦ expression was significantly decreased in the cerebral vessels.
To determine the role of VSMC-specific PPAR␦ function in ischemic brain injury, SMP␦ cKO and LC mice were subjected to transient MCAO for 30 minutes followed by 24 hours reperfusion (nϭ8 to 10). Cerebral infarction, neurological outcomes, and cerebral vascular permeability were determined by 2% 2,3,5-triphenyltetrazolium chloride (TTC) staining and Evans blue extravasation, respectively. In comparison with the LC mice, SMP␦ cKO mice showed a larger cerebral infarct volume ( Figure 1A and 1B) and a significantly more severe neurological deficit ( Figure 1C ) in response to ischemic insults. Of significance, VSMC-selective PPAR␦ deletion also aggravated ischemia-induced BBB disruption by increasing cerebrovascular permeability ( Figure 1D ). Taken together, these results suggest that PPAR␦ in VSMCs plays a critical role in the maintenance of vascular structure and function. Loss of PPAR␦ function in the cerebral vasculature appears to exacerbate ischemic brain damage.
PPAR␦ Deletion in VSMCs Increases Postischemic Inflammatory Responses in Mouse Brain
It is well-established that inflammatory responses contribute to the development of ischemic brain damage. 18 To determine whether genetic deficiency of PPAR␦ in VSMCs affects postischemic inflammatory mechanisms, we examined the expression of several proinflammatory cytokines in the mouse brain after 24 hours MCAO. As indicated in supplemental Figure II , loss of PPAR␦ function in VSMCs had no significant effect on the endogenous expression of most cytokines. However, MCAO caused a significant increase in the mRNA levels of cytokines, including interleukin (IL)-1␤, IL-6, intercellular adhesion molecule (ICAM)-1, and monocyte chemoattractant protein (MCP)-1 in LC mouse brains. Intriguingly, VSMC deletion of PPAR␦ significantly exacer- Figure 1 . The effect of VSMC PPAR␦ on ischemia-induced brain infarction and cerebrovascular permeability. VSMCselective PPAR␦ knockout (SMP␦ cKO) and LC mice were subjected to 30 minutes of MCAO and 24 hours of reperfusion. Coronal sections stained with 2% TTC are shown at different brain levels posterior to the frontal pole (A). Quantitative analysis was performed on infarct volume (B) and neurological deficits (C) in mice after stroke. Quantitative analysis of cerebrovascular permeability was determined 1 hour after Evans blue injection (D). Compared with LC mice, SMP␦ cKO mice show potentiated ischemia-induced brain infarction (nϭ7), neurological outcomes (nϭ7), and cerebrovascular permeability (nϭ6). Data are expressed as meansϮSD. *PϽ0.05 vs the LC group.
bated ischemia-induced elevations of IL-1␤, IL-6, ICAM-1, and MCP-1 mRNA levels, whereas no changes were found in the expression of tumor necrosis factor-␣ and vascular cell adhesion molecule-1 in SMP␦ cKO mouse brains.
VSMC-Selective PPAR␦ Deletion Exacerbates Ischemia-Induced Activation of MMP-9
Activation of MMPs and subsequent degradation of extracellular matrix play a critical role in the pathogenesis of ischemia-induced vascular and neuronal injury. 9, 10 Earlier studies have demonstrated that PPAR␥ is able to negatively regulate MMP activity in various tissues, including the vasculature. 12, 13, 19 To explore whether MMPs function as an important link to VSMC PPAR␦ deletion-triggered neurological dysfunction, we used quantitative PCR and Western blotting to evaluate their temporal profiles ( Figure 2 ). Compared with sham experimental groups, PPAR␦ mRNA expression ( Figure 2A ) and protein levels ( Figure 2B ) were significantly decreased in the wild-type mouse cerebral cortex after 24 and 72 hours of MCAO. Conversely, MMP-9 mRNA ( Figure 2D ) and activity ( Figure 2E ) were induced and increased in the LC mouse cerebral cortex subjected to MCAO. Interestingly, VSMC-selective PPAR␦ deletion further exacerbated activation of MMP-9 but not MMP-2 activity ( Figure 2C through 2E). These results suggest that vascular PPAR␦ negatively modulates MMP-9 expression in the cerebral cortex.
PPAR␦ Negatively Regulates OGD-Induced MMP-9 mRNA and Activity in VSMCs
To further define the molecular mechanisms of MMPs responsible for VSMC PPAR␦ genetic deficiency-mediated ischemic brain injury, we examined PPAR␦ regulatory effects on the expression of MMPs in mouse VSMC culture. As shown in Figure 3 , OGD caused a rapid reduction in PPAR␦ mRNA and protein expression in VSMCs, decreasing at 4 hours and maintaining a lower level at 24 hours after OGD onset ( Figure 3A and 3B). In contrast to OGD-induced reduction of PPAR␦ levels, MMP-9 mRNA and enzymatic activity were gradually increased in VSMCs after OGD, starting at 4 hours and persisting at least to 24 hours after OGD stimuli ( Figure 3D and 3E). Of interest, OGD did not significantly affect MMP-2 mRNA expression and enzymatic activity in cultured VSMCs ( Figure 3C and 3E).
To further explore the contributory role of PPAR␦ in the regulation of MMP-9 activation in VSMCs after OGD exposure, gain or loss of PPAR␦ function was achieved by infecting cells with either an adenovirus carrying PPAR␦ or a retrovirus carrying shPPAR␦. The success of the gain of PPAR␦ function approach was demonstrated by the high percentage of infected VSMCs (supplemental Figure IIIA with GW 501516 or genetic modulation of PPAR␦ has no effect on MMP-2 mRNA and enzymatic activity after OGD exposure ( Figure 4B , 4E, and 4H). Taken together, these results suggest that PPAR␦ activation can repress MMP-9 activity in VSMCs after OGD treatment.
PPAR␦ Binds Directly to the PPAR Response Element Site in the MMP-9 Promoter Region and Transrepresses Its Expression
To further study whether PPAR␦ suppresses MMP-9 expression in a transcriptional manner, we performed a functional analysis of potential PPAR response elements (PPREs) in the mouse MMP-9 promoter. As indicated in Figure 5A , we identified a putative PPAR␦ binding site in the promoter of the MMP-9 gene at the location of Ϫ944 to Ϫ921 bp. To determine the functionality of this PPRE in the MMP-9 gene promoter, we cloned a 1309 bp (Ϫ1253/ϩ55) promoter of the mouse MMP-9 gene into a luciferase reporter vector, and the transcriptional response of the MMP-9 promoter to PPAR␦ was performed using a luciferase transcriptional assay in vitro. HEK 293 cells were transfected with a 1.3-kb promoter (MMP-9 PPRE WT) or a promoter with the corresponding site-directed mutation on the identified PPRE (MMP-9 PPRE mut). Cells were also infected with either an adenovirus carrying PPAR␦ to overexpress PPAR␦, or adenoviral GFP as an infection control. As shown in Figure 5B , PPAR␦ overexpression significantly reduced the transcriptional activity of the MMP-9 1.3-kb promoter. Moreover, luciferase activities from the MMP-9 1.3-kb promoter driven by the mutated PPRE did not respond to PPAR␦ overexpression, indicating that the predicted PPRE site in the promoter region of MMP-9 is responsible for PPAR␦ transrepression of MMP-9 expression in vitro. Moreover, PPAR␦ inhibition of MMP-9
promoter activity was further enhanced by cotreatment with the PPAR␦ agonist GW501516. However, cotreatment with the PPAR␦ antagonist GSK 0660 reversed PPAR␦-induced inhibition of MMP-9 promoter activity, suggesting this effect is ligand-dependent ( Figure 5C ). Next, chromatin domains in the MMP-9 promoter were scanned for PPAR␦ binding by chromatin immunoprecipitation (ChIP) analysis in VSMCs. As shown in Figure 5D , consistent with PPRE-driven transcriptional activity, adenovirus-mediated overexpression of PPAR␦ is detectably bound to the PPRE site located between Ϫ944 to Ϫ921 bp upstream of the transcription start site. The specificity of the ChIP assay was confirmed by using one set of primers that amplified a nonspecific region located at nucleotides Ϫ3613 to Ϫ3282 of the MMP-9 promoter, as PPAR␦ does not bind to this nonspecific region ( Figure 5E ). An isotypic IgG antibody was used as a negative immunoprecipitation control. These data strongly suggest that in the context of chromatin, the PPRE between nucleotides Ϫ944 to Ϫ921 appears to be functional, showing binding of PPAR␦ to the MMP-9 promoter.
Taken together, these data document that the MMP-9 gene is a novel target of PPAR␦ transcriptional repression.
Inhibition of MMPs in SMP␦ cKO Mice Attenuates Cerebrovascular Disruption and Ischemic Brain Injury In Vivo
To further determine MMP-9 as a key modulator in PPAR␦mediated vaso-and neuroprotection in vivo, we stereotactically delivered a lentivirus carrying mouse shMMP-9 or GFP into the ischemic region in SMP␦ cKO mice 4 weeks before MCAO, followed by MCAO and 24 hours reperfusion. As shown in Figure 6 , lentivirus-mediated cerebral MMP-9 knockdown obviously reduced ischemic brain infarction (Fig-Figure 3 . The expression of PPAR␦ and MMP activity in mouse VSMC culture after OGD. OGD resulted in a timedependent decrease in PPAR␦ mRNA expression (A) and protein levels (B), starting at 4 hours post-OGD and persisting at least to 24 hours after OGD. In contrast, OGD triggered an increase in MMP-9 mRNA (D) and enzymatic activity (E), initiating at 4 hours post-OGD, and persisting to at least 24 hours after OGD. Of note, ODG had no significant effects on MMP-2 mRNA and enzymatic activity in VSMCs (C and E). *PϽ0.05 vs non-OGD controls.
ure 6A and 6D) and neurological outcomes ( Figure 6E ). Moreover, this treatment also effectively improved cerebrovascular permeability in SMP␦ cKO mice ( Figure 6F ). The specificity of lentivirus-mediated inhibition of MMP-9 in the cerebral cortex was confirmed by real-time PCR ( Figure 6B ) and gelatin-based zymography ( Figure 6C) , showing a unique reduction in MMP-9, but not MMP-2 mRNA levels and activity. These results further demonstrate that MMP-9 functions as a major downstream contributor to ischemic brain damage triggered by genetic deletion of PPAR␦ in VSMCs.
Discussion
In this study, we addressed the potential role of vascular PPAR␦ in ischemic brain injury. We demonstrated for the first time that VSMC-selective deletion of PPAR␦ led to much more severe BBB breakdown, inflammatory responses, and neuronal loss in mice after focal cerebral ischemia. We further identified MMP-9 as a direct downstream target of PPAR␦-mediated transrepression at the transcriptional level. This inhibitory pathway is responsible for the contributory role of vascular PPAR␦ in the protection of the cerebral vasculature and brain after ischemic insults.
It has been suggested recently that PPAR␦ plays an important neuroprotective role and that its agonists may be useful for the potential treatment of stroke. 7, 20 For example, PPAR␦-null mice showed significantly greater infarct sizes in stroke versus wild-type animals. 21 However, the specific roles of vascular PPAR␦ in the pathogenesis of stroke have not yet been investigated in either in vitro or in vivo settings, although PPAR␦ is extensively expressed in cerebral vessels. 22, 23 Similar to PPAR␥ and PPAR␣, PPAR␦ displays essential regulatory roles in vascular biology, as well as several pathological conditions, such as atherosclerosis and cardiovascular diseases. 24 -26 In vascular endothelial progenitor cells, PPAR␦ activation has been previously reported to stimulate proliferation and attenuate apoptosis through Aktdependent signaling cascades. 27 In addition, we have recently documented that PPAR␦ plays a protective role in cerebral vascular endothelial cells after ischemic insults via a microRNAmediated apoptotic mechanism. 14 Also, we have previously reported that PPAR␦ is expressed in VSMCs and upregulated after vascular injury to increase VSMC proliferation. 15 Conversely, Lim et al reported that the PPAR␦ agonist L-165041 suppresses rat VSMC proliferation and attenuates neointima formation in the carotid artery balloon injury model. 28 A possible explanation of these inconsistent results may be attributable to PPAR␦-dependent or -independent mechanisms in VSMC proliferation. Also, recent in vivo data from others suggest an atheroprotective role of PPAR␦ agonists by targeting multiple proinflammatory pathways. 24, 26 In this study, we report for the first time that PPAR␦ in VSMCs provides both vaso-and neuroprotection against ischemic insults. We found that OGD induced a reduction in PPAR␦ expression but an increase in MMP-9 activity, and gain of PPAR␦ function by adenovirus effectively decreased OGDinduced activation of MMP-9. Moreover, we documented that selective deletion of PPAR␦ in VSMCs exacerbated ischemia-triggered BBB damage and postischemic inflammation, resulting in a larger infarct brain size. Thus, our data provide the first evidence that PPAR␦ in VSMCs can function as a novel modulator in the regulation of ischemic vascular and brain injury.
In the present study, the mechanisms responsible for OGDinduced reduction of PPAR␦ in VSMCs could be complicated. MicroRNA-mediated mRNA degradation and translational repression may be possible mechanisms involved in the downregulation of PPAR␦ because hypoxia has been reported to dramatically alter microRNA profiles. 29 For example, several recent studies have demonstrated that microRNA-27 can inhibit adipocyte differentiation 30 or promote lipopolysaccharide-induced inflammation in human macrophages 31 via suppressing PPAR␥ expression. Moreover, microRNA-122 has been recently identified as a negative regulator of the PPAR␣ and PPAR␦ coactivator Smarcd1/Baf60a in hepatic metabolic control. 32 Thus, further studies are needed to investigate microRNA-mediated PPAR␦ dysfunction after ischemic brain injury.
The vascular pathology observed in ischemic stroke suggests a pathogenic process involving the breakdown of the vascular basement membrane, leading to a compromised BBB structural integrity, edema, neuroinflammation, and eventual inflammatory brain damage. Over the last 2 decades, cumulative data have demonstrated that the MMP family plays a critical role in the regulation of vascular base membrane structural integrity during ischemic-triggered vascular injury. 33, 34 In particular, MMP-2 and -9 have received considerable attention in cerebral ischemia because of their contributory role in the proteolytic degradation of base membrane components, leading to increased BBB permeability, edema, and hemorrhagic transformation. 9, 10, 35 Indeed, MMP-2 and -9 have been shown to be activated widely in the ischemic regions, and inhibition of their activities through genetic or pharmacological approaches effectively protects against ischemic brain or vascular injury in rodent stroke models. For example, an earlier observation demonstrated that MMP-2 injected into the brain results in an opening of the BBB, with subsequent hemorrhage around the blood vessels. 36 By contrast, treatment with MMP inhibitors reduces these effects. 33, 34 Further evidence that MMPs mediate Figure 5 . Functional analysis of a PPRE site located in the mouse MMP-9 promoter. A, Schematic representation of a luciferase reporter construct containing Ϸ1.3 kb of the 5Ј-upstream sequences of the mouse MMP-9 gene. A putative PPAR␦ binding site was demonstrated in the promoter of MMP-9 at locations of Ϫ944/Ϫ921 bp. The translation start site is numbered as ϩ1. B and C, Luciferase reporter assays were performed by transfecting HEK 293 cells with a luciferase reporter vector carrying either an MMP-9 1.3-kb wild-type promoter (MMP-9 PPRE WT) or an MMP-9 promoter with a mutated PPRE (MMP-9 PPRE mut.). Transcriptional activity of MMP-9 was reduced on overexpression of PPAR␦ in HEK 293 cells containing the MMP-9 wild-type but not mutated promoter (B). MMP-9 transcriptional activity was further inhibited by the PPAR␦ agonist GW 501516 (1 mol/L) but reversed by the PPAR␦ antagonist GSK 0660 (1 mol/L) (C). D and E, ChIP assays showing PPAR␦ binding to the putative PPRE site (Ϫ944 to Ϫ921 bp) (D) but not a distal region (Ϫ3613 to Ϫ3282 bp) (E) in the mouse MMP-9 promoter. Mouse VSMCs were infected with an adenovirus carrying GFP or PPAR␦ for 48 hours. DNA from PPAR␦ antibodyimmunoprecipitated chromatin and input were subjected to PCR analysis using 2 pairs of primers covering either a region containing the PPRE site or a distal fragment in the mouse MMP-9 promoter. Data are expressed as meansϮSD. *PϽ0.05 vs Ad.GFP or no transfection control (NTC) group.
BBB injury includes observations in MMP-9 knockout mice, which display reduced infarct size and less BBB damage or hemorrhagic transformation compared with wild-type mice after focal ischemia. 9, 10 Consistent with these previous reports, we found that MMP-9 activity is activated in cultured VSMCs in a time-dependent manner after ODG exposure. Moreover, there is greater potentiation of MMP-9 activity in the brains of SMP␦ cKO mice after focal cerebral ischemia when compared with LC mice, and this increase is also associated with a larger scale of released ischemic proinflammatory cytokines. Of significance, loss of MMP-9 function by lentivirus approach significantly reduces ischemic vascular and brain injury in SMP␦ cKO mice, implying that PPAR␦ gene deletion-induced ischemic vascular and brain damage results from upregulated MMP-9 levels.
Recent studies have revealed that activation of another PPAR subtype, PPAR␥, may directly inhibit MMP-9 expression or activity to execute its neuroprotective effects in ischemic stroke. 19 In the vascular system, activation of the same PPAR isoform by different PPAR␥ agonists has also been reported to decrease MMP-9 levels, thereby reducing VSMC proliferation and migration and effectively delaying the initiation and progression of atherosclerotic lesions, restenosis, and vessel lesions in experimental animal models. 12, 13 With regard to these previous findings, we hypothesized that inhibition of MMP-9 is also responsible for VSMC PPAR␦-mediated vascular and brain protection after focal cerebral ischemia observed in the present study. Indeed, we documented here for the first time that PPAR␦ overexpression by adenovirus, and also activation of PPAR␦ by the PPAR␦ agonist GW501516 attenuated OGD-triggered induction of MMP-9 mRNA and activity in VSMC culture. In contrast, inhibition of PPAR␦ by retrovirus-mediated PPAR␦ RNA interference effectively reversed these effects. The latter study is well-confirmed by our in vivo evidence that VSMC-selective deletion of PPAR␦ results in a significantly higher level of MMP-9 enzymatic activity in ischemic brain regions compared with the littermate control mice. Importantly, by using PPAR␦ transcriptional activity analysis and a ChIP assay, we have further identified that PPAR␦ may negatively regulate MMP-9 activity via a transcriptional mechanism. To our knowledge, we are the first to report that MMP-9 is under the control of PPAR␦-mediated transcriptional repression in vascular cells.
In conclusion, our data clearly identify a protective action of VSMC PPAR␦ on cerebral ischemia-induced vascular and brain injury. We also define PPAR␦-mediated transcriptional suppression of MMP-9 as a major mechanism responsible for this effect. Understanding the mechanisms of vascular PPAR␦-mediated brain protection elucidated in this study may be important for uncovering the pathogenesis of cerebral ischemia. Expectedly, pharmacological activation of PPAR␦ may provide a novel therapy for stroke-induced vascular and neuronal damage.
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